Microvascular dysfunction after successful primary PCI is frequent and contributes to poor outcomes in STEMI.
RZNOMICS advance its lead compound, a gene therapy produced using CEVEC's CAP® Ad Technology, into clinical development
CEVEC’s license partner RZNOMICS Inc. receives approval to initiate clinical development of CAP® Ad Technology-produced gene therapy vector in liver cancer patients
300 patients have been treated with PiCSO®
CryoTherapeutics, focusing on the development, demonstration of clinical benefit, and early-stage commercialization of a proprietary cryotherapy system for use in the treatment of coronary artery disease that causes heart attacks, announces today that it has received additional funding of € 12.3 million.